Method for the early diagnosis of cancer

Claim 1

A method of detecting cancer in humans which comprises the steps of: a. obtaining a blood sample from a patient to be screened for cancer; b. separating cellular matter from the blood plasma of said sample; c. treating said blood plasma with Brockmann aluminum oxide; d. subjecting a portion of the plasma treated with Brockmann aluminum oxide to spectrophotometric analysis at wavelengths of 562, 576 and 610 nm to obtain first extinction values at each of said wavelengths; e. diluting another portion of the plasma treated with Brockmann aluminum oxide to dilution with a standard diluent to produce a diluted specimen; f. subjecting said diluted specimen to spectrophotometric analysis at wavelengths of 562, 576 and 610 nm to obtain respective second values of total extinction at said wavelengths; g. deriving a value A corresponding to the percentage decrease in the first and second values at said wavelengths of 576 nm deriving a value B corresponding to the difference in the extinction of second values between the wavelengths of 562nm and 610 nm, and deriving a value C corresponding to the difference between the change in first extinction values at 576 nm to 562 nm and the change in said second values from 576 nm to 562 nm; and h. deriving a coefficient K = (A + B/C) where a K value less than 95 represents a statistically significant probability of cancer and a K value above 105 represents a statistically significant probability absence of cancer.

Claim 2

A method of detecting cancer in humans which comprises the steps of: a. obtaining a blood sample from a patient to be screened for cancer; b. separating cellular matter from the blood plasma of said sample; c. treating said blood plasma with Brockmann aluminum oxide; d. subjecting a portion of the plasma treated with Brockmann aluminum oxide to spectrophotometric analysis at wavelengths of 562, 576 and 610 nm to obtain first extinction values at each of said wavelengths; e. diluting another portion of the plasma treated with Brockmann aluminum oxide to dilution with a standard diluent to produce a diluted specimen; f. subjecting said diluted specimen to spectrophotometric analysis at wavelengths of 562, 576 and 610 nm to obtain respective second values of total extinction at said wavelengths; g. deriving a value A corresponding to the percentage decrease in the first and second values at said wavelengths of 576 nm deriving a value B corresponding to the difference in the extinction of second values between the wavelengths of 562nm and 610 nm, and deriving a value C corresponding to the difference between the change in first extinction values at 576 nm to 562 nm and the change in said second values from 576 nm to 562 nm; and h. deriving a coefficient K = (A + B/C) where a K value less than 95 represents a statistically significant probability of cancer and a K value above 105 represents a statistically significant probability absence of cancer.